EUVIMEDEUVIMED entdecken
Open Access

Utilization of Biologic Disease‐Modifying Antirheumatic Therapy in Patients With Rheumatoid Arthritis and Recently Diagnosed Breast Cancer

Juan I Ruiz iD, Xiudong Lei, Chi-Fang Wu, Hui Zhao, Sharon H Giordano, Suja S Rajan, Maria E Suarez-Almazor iD

Arthritis Care & Research · 2024

DOI: 10.1002/acr.25306 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis Care & Research, 2024. Verfasst von Juan I Ruiz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Breast Neoplasms, Antirheumatic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Komen, California Department of Public Health pursuant to California Health and Safety Code Section 103885.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Biologic disease‐modifying antirheumatic drugs (bDMARDs) are immunosuppressants, and there have been concerns that they might impact tumor immunity in patients with cancer with rheumatoid arthritis (RA). The purpose of this study was to describe the utilization trends of bDMARD in patients with RA after breast cancer (BC) diagnosis.

Methods

We performed a retrospective cohort study of adults with RA and BC (2008 onward) from Optum's de‐identified Clinformatics® Data Mart Database (CDM); the Surveillance, Epidemiology, and End Results Program (SEER) Medicare; and the Texas Cancer Registry (TCR) Medicare databases. We evaluated bDMARD utilization trends during the first three years after BC. We conducted multivariable logistic regression to evaluate the association of utilization with patient characteristics.

Results

A total 1,412 patients were identified in CDM and 1,439 patients in SEER/TCR‐Medicare. During the three months before BC diagnosis, 28.2% (CDM) and 26.9% (SEER/TCR‐Medicare) patients had received bDMARDs. Within the first three years after diagnosis, 24.1% (CDM) and 26.4% (SEER/TCR‐Medicare) were receiving bDMARDs. About 70% of the patients in the two cohorts received glucocorticoids with no significant time trend increases. The largest predictor of bDMARD utilization was prior use before BC (CDM: odds ratio [OR] 27.15, 95% confidence interval [CI] 19.29–38.19; SEER/TCR: OR 18.98, 95% CI 13.72–26.26). Regional and distant BC compared to in situ or localized were also associated with lower bDMARDs utilization in SEER/TCR‐Medicare (OR 0.54, 95% CI 0.36–0.82; OR 0.31, 95% CI 0.13–0.77, respectively).

Conclusion

The utilization of tumor necrosis factor inhibitors and other bDMARDs in patients with RA and recent BC has not increased since 2008. Glucocorticoids utilization remained high. The largest predictor of bDMARD utilization was prior use before BC. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidBreast NeoplasmsAntirheumatic AgentsHumansFemaleRetrospective StudiesAgedMiddle AgedUnited StatesBiological ProductsSEER ProgramMedicareAged, 80 and overDatabases, Factual

Substanzen

Antirheumatic AgentsBiological Products

Autor:innen und Institutionen

  • Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Department of Management, Policy and Community Heath, School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas.

ORCID-Profile: Juan I Ruiz, Maria E Suarez-Almazor

Förderung

  • NCI NIH HHS
  • Komen
  • California Department of Public Health pursuant to California Health and Safety Code Section 103885
  • Public Health Institute
  • Centers for Disease Control and Prevention's National Program of Cancer Registries
  • The University of Texas MD Anderson's Cancer Center
  • NIAMS NIH HHS
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases

Zitieren

APA

Ruiz, J. I., Lei, X., Wu, C. F., Zhao, H., Giordano, S. H., Rajan, S. S., & Suarez-Almazor, M. E. (2024). Utilization of Biologic Disease‐Modifying Antirheumatic Therapy in Patients With Rheumatoid Arthritis and Recently Diagnosed Breast Cancer. Arthritis Care & Research. https://doi.org/10.1002/acr.25306

Vancouver

Ruiz JI, Lei X, Wu CF, Zhao H, Giordano SH, Rajan SS, et al. Utilization of Biologic Disease‐Modifying Antirheumatic Therapy in Patients With Rheumatoid Arthritis and Recently Diagnosed Breast Cancer. Arthritis Care & Research. 2024. doi:10.1002/acr.25306

BibTeX
@article{Ruiz2024,
  author = {Ruiz, Juan I and Lei, Xiudong and Wu, Chi-Fang and Zhao, Hui and Giordano, Sharon H and Rajan, Suja S and Suarez-Almazor, Maria E},
  title = {Utilization of Biologic Disease‐Modifying Antirheumatic Therapy in Patients With Rheumatoid Arthritis and Recently Diagnosed Breast Cancer},
  journal = {Arthritis Care & Research},
  year = {2024},
  doi = {10.1002/acr.25306}
}
Kostenlos starten →